Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 524

1.

Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

Andrabi R, Bhiman JN, Burton DR.

Curr Opin Immunol. 2018 May 15;53:143-151. doi: 10.1016/j.coi.2018.04.025. [Epub ahead of print] Review.

PMID:
29775847
2.

Global site-specific analysis of glycoprotein N-glycan processing.

Cao L, Diedrich JK, Ma Y, Wang N, Pauthner M, Park SR, Delahunty CM, McLellan JS, Burton DR, Yates JR, Paulson JC.

Nat Protoc. 2018 Jun;13(6):1196-1212. doi: 10.1038/nprot.2018.024. Epub 2018 May 3.

PMID:
29725121
3.

Fetal demise and failed antibody therapy during Zika virus infection of pregnant macaques.

Magnani DM, Rogers TF, Maness NJ, Grubaugh ND, Beutler N, Bailey VK, Gonzalez-Nieto L, Gutman MJ, Pedreño-Lopez N, Kwal JM, Ricciardi MJ, Myers TA, Julander JG, Bohm RP, Gilbert MH, Schiro F, Aye PP, Blair RV, Martins MA, Falkenstein KP, Kaur A, Curry CL, Kallas EG, Desrosiers RC, Goldschmidt-Clermont PJ, Whitehead SS, Andersen KG, Bonaldo MC, Lackner AA, Panganiban AT, Burton DR, Watkins DI.

Nat Commun. 2018 Apr 24;9(1):1624. doi: 10.1038/s41467-018-04056-4.

4.

Unprecedented Role of Hybrid N-Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies.

Shivatare VS, Shivatare SS, Lee CD, Liang CH, Liao KS, Cheng YY, Saidachary G, Wu CY, Lin NH, Kwong PD, Burton DR, Wu CY, Wong CH.

J Am Chem Soc. 2018 Apr 18;140(15):5202-5210. doi: 10.1021/jacs.8b00896. Epub 2018 Apr 9.

PMID:
29578688
5.

A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope.

Zhou T, Zheng A, Baxa U, Chuang GY, Georgiev IS, Kong R, O'Dell S, Shahzad-Ul-Hussan S, Shen CH, Tsybovsky Y, Bailer RT, Gift SK, Louder MK, McKee K, Rawi R, Stevenson CH, Stewart-Jones GBE, Taft JD, Waltari E, Yang Y, Zhang B, Shivatare SS, Shivatare VS, Lee CD, Wu CY; NISC Comparative Sequencing Program, Mullikin JC, Bewley CA, Burton DR, Polonis VR, Shapiro L, Wong CH, Mascola JR, Kwong PD, Wu X.

Immunity. 2018 Mar 20;48(3):500-513.e6. doi: 10.1016/j.immuni.2018.02.013. Epub 2018 Mar 13.

PMID:
29548671
6.

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.

Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Hedestam GBK, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME.

JCI Insight. 2018 Mar 8;3(5). pii: 97018. doi: 10.1172/jci.insight.97018. [Epub ahead of print]

7.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Wagh K, Seaman MS, Zingg M, Fitzsimons T, Barouch DH, Burton DR, Connors M, Ho DD, Mascola JR, Nussenzweig MC, Ravetch J, Gautam R, Martin MA, Montefiori DC, Korber B.

PLoS Pathog. 2018 Mar 5;14(3):e1006860. doi: 10.1371/journal.ppat.1006860. eCollection 2018 Mar.

8.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2018 Jan 23;22(4):1103. doi: 10.1016/j.celrep.2017.10.089. Epub 2018 Jan 28. No abstract available.

9.

Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.

Walker LM, Burton DR.

Nat Rev Immunol. 2018 May;18(5):297-308. doi: 10.1038/nri.2017.148. Epub 2018 Jan 30. Review.

PMID:
29379211
10.

Taking down defenses to improve vaccines.

Teijaro JR, Burton DR.

Science. 2018 Jan 19;359(6373):277-278. doi: 10.1126/science.aar5421. No abstract available.

PMID:
29348225
11.

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

Landais E, Murrell B, Briney B, Murrell S, Rantalainen K, Berndsen ZT, Ramos A, Wickramasinghe L, Smith ML, Eren K, de Val N, Wu M, Cappelletti A, Umotoy J, Lie Y, Wrin T, Algate P, Chan-Hui PY, Karita E; IAVI Protocol C Investigators; IAVI African HIV Research Network, Ward AB, Wilson IA, Burton DR, Smith D, Pond SLK, Poignard P.

Immunity. 2017 Nov 21;47(5):990-1003.e9. doi: 10.1016/j.immuni.2017.11.002.

PMID:
29166592
12.

Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.

Andrabi R, Su CY, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DR.

Immunity. 2017 Nov 21;47(5):1004. doi: 10.1016/j.immuni.2017.10.012. No abstract available.

13.

Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.

Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A, Cottrell CA, Havenar-Daughton C, Ozorowski G, Georgeson E, Kalyuzhniy O, Willis JR, Kubitz M, Adachi Y, Reiss SM, Shin M, de Val N, Ward AB, Crotty S, Burton DR, Schief WR.

Nat Commun. 2017 Nov 21;8(1):1655. doi: 10.1038/s41467-017-01549-6.

14.

Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques.

Magnani DM, Rogers TF, Beutler N, Ricciardi MJ, Bailey VK, Gonzalez-Nieto L, Briney B, Sok D, Le K, Strubel A, Gutman MJ, Pedreño-Lopez N, Grubaugh ND, Silveira CGT, Maxwell HS, Domingues A, Martins MA, Lee DE, Okwuazi EE, Jean S, Strobert EA, Chahroudi A, Silvestri G, Vanderford TH, Kallas EG, Desrosiers RC, Bonaldo MC, Whitehead SS, Burton DR, Watkins DI.

Sci Transl Med. 2017 Oct 4;9(410). pii: eaan8184. doi: 10.1126/scitranslmed.aan8184.

PMID:
28978754
15.

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, Su CY, Sok D, Khan SN, Garces F, Pritchard LK, Wyatt RT, Ward AB, Crispin M, Wilson IA, Burton DR.

Cell Rep. 2017 Oct 3;21(1):222-235. doi: 10.1016/j.celrep.2017.09.024. Erratum in: Cell Rep. 2018 Jan 23;22(4):1103.

16.

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.

Julg B, Liu PT, Wagh K, Fischer WM, Abbink P, Mercado NB, Whitney JB, Nkolola JP, McMahan K, Tartaglia LJ, Borducchi EN, Khatiwada S, Kamath M, LeSuer JA, Seaman MS, Schmidt SD, Mascola JR, Burton DR, Korber BT, Barouch DH.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaao4235. doi: 10.1126/scitranslmed.aao4235.

17.

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.

Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, Lange C, Leuschner WD, Kruip J, Sendak R, Kwon YD, Zhou T, Chen X, Bailer RT, Wang K, Choe M, Tartaglia LJ, Barouch DH, O'Dell S, Todd JP, Burton DR, Roederer M, Connors M, Koup RA, Kwong PD, Yang ZY, Mascola JR, Nabel GJ.

Science. 2017 Oct 6;358(6359):85-90. doi: 10.1126/science.aan8630. Epub 2017 Sep 20.

PMID:
28931639
18.

Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.

Andrabi R, Su CY, Liang CH, Shivatare SS, Briney B, Voss JE, Nawazi SK, Wu CY, Wong CH, Burton DR.

Immunity. 2017 Sep 19;47(3):524-537.e3. doi: 10.1016/j.immuni.2017.08.006. Epub 2017 Sep 12. Erratum in: Immunity. 2017 Nov 21;47(5):1004.

PMID:
28916265
19.

Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer.

He L, Lin X, de Val N, Saye-Francisco KL, Mann CJ, Augst R, Morris CD, Azadnia P, Zhou B, Sok D, Ozorowski G, Ward AB, Burton DR, Zhu J.

Front Immunol. 2017 Aug 24;8:1025. doi: 10.3389/fimmu.2017.01025. eCollection 2017.

20.

Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.

Magnani DM, Silveira CGT, Ricciardi MJ, Gonzalez-Nieto L, Pedreño-Lopez N, Bailey VK, Gutman MJ, Maxwell HS, Domingues A, Costa PR, Ferrari L, Goulart R, Martins MA, Martinez-Navio JM, Fuchs SP, Kalil J, Timenetsky MDC, Wrammert J, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI.

J Virol. 2017 Oct 27;91(22). pii: e00867-17. doi: 10.1128/JVI.00867-17. Print 2017 Nov 15.

21.

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.

Julg B, Tartaglia LJ, Keele BF, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH.

Sci Transl Med. 2017 Sep 6;9(406). pii: eaal1321. doi: 10.1126/scitranslmed.aal1321.

22.

Correction: Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies.

Nandin IS, Fong C, Deantonio C, Torreno-Pina JA, Pecetta S, Maldonado P, Gasparrini F, Ordovas-Montanes J, Kazer SW, Kjaer S, Borley DW, Nair U, Coleman JA, Lingwood D, Shalek AK, Meffre E, Poignard P, Burton DR, Batista FD.

J Exp Med. 2017 Sep 4;214(9):2811. doi: 10.1084/jem.2017063307262017c. Epub 2017 Aug 21. No abstract available.

23.

Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors.

Rogers TF, Goodwin EC, Briney B, Sok D, Beutler N, Strubel A, Nedellec R, Le K, Brown ME, Burton DR, Walker LM.

Sci Immunol. 2017 Aug 18;2(14). pii: eaan6809. doi: 10.1126/sciimmunol.aan6809.

24.

Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.

Julg B, Sok D, Schmidt SD, Abbink P, Newman RM, Broge T, Linde C, Nkolola J, Le K, Su D, Torabi J, Pack M, Pegu A, Allen TM, Mascola JR, Burton DR, Barouch DH.

J Virol. 2017 Sep 27;91(20). pii: e01187-17. doi: 10.1128/JVI.01187-17. Print 2017 Oct 15.

25.

Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys.

Magnani DM, Ricciardi MJ, Bailey VK, Gutman MJ, Pedreño-Lopez N, Silveira CGT, Maxwell HS, Domingues A, Gonzalez-Nieto L, Su Q, Newman RM, Pack M, Martins MA, Martinez-Navio JM, Fuchs SP, Rakasz EG, Allen TM, Whitehead SS, Burton DR, Gao G, Desrosiers RC, Kallas EG, Watkins DI.

Mol Ther. 2017 Oct 4;25(10):2323-2331. doi: 10.1016/j.ymthe.2017.06.020. Epub 2017 Jul 24.

PMID:
28750738
26.

Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies.

Sanjuan Nandin I, Fong C, Deantonio C, Torreno-Pina JA, Pecetta S, Maldonado P, Gasparrini F, Ordovas-Montanes J, Kazer SW, Kjaer S, Borley DW, Nair U, Coleman JA, Lingwood D, Shalek AK, Meffre E, Poignard P, Burton DR, Batista FD.

J Exp Med. 2017 Jul 24. pii: jem.20170633. doi: 10.1084/jem.20170633. [Epub ahead of print] Erratum in: J Exp Med. 2017 Aug 21;:.

27.

Vaccine-induced immune responses against both Gag and Env improve control of simian immunodeficiency virus replication in rectally challenged rhesus macaques.

Martins MA, Shin YC, Gonzalez-Nieto L, Domingues A, Gutman MJ, Maxwell HS, Castro I, Magnani DM, Ricciardi M, Pedreño-Lopez N, Bailey V, Betancourt D, Altman JD, Pauthner M, Burton DR, von Bredow B, Evans DT, Yuan M, Parks CL, Ejima K, Allison DB, Rakasz E, Barber GN, Capuano S 3rd, Lifson JD, Desrosiers RC, Watkins DI.

PLoS Pathog. 2017 Jul 21;13(7):e1006529. doi: 10.1371/journal.ppat.1006529. eCollection 2017 Jul.

28.

Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows.

Sok D, Le KM, Vadnais M, Saye-Francisco KL, Jardine JG, Torres JL, Berndsen ZT, Kong L, Stanfield R, Ruiz J, Ramos A, Liang CH, Chen PL, Criscitiello MF, Mwangi W, Wilson IA, Ward AB, Smider VV, Burton DR.

Nature. 2017 Aug 3;548(7665):108-111. doi: 10.1038/nature23301. Epub 2017 Jul 20.

29.

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.

Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA, Eroshkin AM, Guenaga J, Kaushik K, Kulp DW, Liu J, McCoy LE, Oom AL, Ozorowski G, Post KW, Sharma SK, Steichen JM, de Taeye SW, Tokatlian T, Torrents de la Peña A, Butera ST, LaBranche CC, Montefiori DC, Silvestri G, Wilson IA, Irvine DJ, Sanders RW, Schief WR, Ward AB, Wyatt RT, Barouch DH, Crotty S, Burton DR.

Immunity. 2017 Jun 20;46(6):1073-1088.e6. doi: 10.1016/j.immuni.2017.05.007.

30.

A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus.

Magnani DM, Silveira CGT, Rosen BC, Ricciardi MJ, Pedreño-Lopez N, Gutman MJ, Bailey VK, Maxwell HS, Domingues A, Gonzalez-Nieto L, Avelino-Silva VI, Trindade M, Nogueira J, Oliveira CS, Maestri A, Felix AC, Levi JE, Nogueira ML, Martins MA, Martinez-Navio JM, Fuchs SP, Whitehead SS, Burton DR, Desrosiers RC, Kallas EG, Watkins DI.

PLoS Negl Trop Dis. 2017 Jun 12;11(6):e0005655. doi: 10.1371/journal.pntd.0005655. eCollection 2017 Jun.

31.

Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples.

Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G, Robles-Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, de Jesus JG, Giovanetti M, Hill SC, Black A, Bedford T, Carroll MW, Nunes M, Alcantara LC Jr, Sabino EC, Baylis SA, Faria NR, Loose M, Simpson JT, Pybus OG, Andersen KG, Loman NJ.

Nat Protoc. 2017 Jun;12(6):1261-1276. doi: 10.1038/nprot.2017.066. Epub 2017 May 24.

32.

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.

Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, Cottrell CA, Nieusma T, Blattner C, Paulson JC, Klasse PJ, Wilson IA, Burton DR, Ward AB.

Immunity. 2017 Apr 18;46(4):690-702. doi: 10.1016/j.immuni.2017.03.017.

33.

Immunochemical engineering of cell surfaces to generate virus resistance.

Xie J, Sok D, Wu NC, Zheng T, Zhang W, Burton DR, Lerner RA.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4655-4660. doi: 10.1073/pnas.1702764114. Epub 2017 Apr 10.

34.

Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.

Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park SR, Sok D, Su CY, Delahunty CM, Menis S, Andrabi R, Guenaga J, Georgeson E, Kubitz M, Adachi Y, Burton DR, Schief WR, Yates JR III, Paulson JC.

Nat Commun. 2017 Mar 28;8:14954. doi: 10.1038/ncomms14954.

35.

Developing an HIV vaccine.

Haynes BF, Burton DR.

Science. 2017 Mar 17;355(6330):1129-1130. doi: 10.1126/science.aan0662. Epub 2017 Mar 16. No abstract available.

36.

Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.

Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ, Tang J, Sok D, Burton DR, Law M, Ward AB, He L, Zhu J.

MBio. 2017 Feb 28;8(1). pii: e00036-17. doi: 10.1128/mBio.00036-17.

37.

Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.

Irimia A, Serra AM, Sarkar A, Jacak R, Kalyuzhniy O, Sok D, Saye-Francisco KL, Schiffner T, Tingle R, Kubitz M, Adachi Y, Stanfield RL, Deller MC, Burton DR, Schief WR, Wilson IA.

PLoS Pathog. 2017 Feb 22;13(2):e1006212. doi: 10.1371/journal.ppat.1006212. eCollection 2017 Feb.

38.

What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.

Burton DR.

Cold Spring Harb Perspect Biol. 2017 Nov 1;9(11). pii: a030262. doi: 10.1101/cshperspect.a030262. Review.

39.

Identification and specificity of broadly neutralizing antibodies against HIV.

McCoy LE, Burton DR.

Immunol Rev. 2017 Jan;275(1):11-20. doi: 10.1111/imr.12484. Review.

40.

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP Jr, Bjorkman PJ, Nussenzweig MC.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaal2144. doi: 10.1126/scitranslmed.aal2144.

41.

Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.

Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndabambi N, Druz A, Asokan M, Burton DR, Connors M, Abdool Karim SS, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL.

PLoS Pathog. 2017 Jan 11;13(1):e1006074. doi: 10.1371/journal.ppat.1006074. eCollection 2017 Jan.

42.

The use of abrasive polishing and laser processing for developing polyurethane surfaces for controlling fibroblast cell behaviour.

Irving M, Murphy MF, Lilley F, French PW, Burton DR, Dixon S, Sharp MC.

Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:690-697. doi: 10.1016/j.msec.2016.10.067. Epub 2016 Nov 2.

PMID:
27987762
43.

Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.

Havenar-Daughton C, Carnathan DG, Torrents de la Peña A, Pauthner M, Briney B, Reiss SM, Wood JS, Kaushik K, van Gils MJ, Rosales SL, van der Woude P, Locci M, Le KM, de Taeye SW, Sok D, Mohammed AUR, Huang J, Gumber S, Garcia A, Kasturi SP, Pulendran B, Moore JP, Ahmed R, Seumois G, Burton DR, Sanders RW, Silvestri G, Crotty S.

Cell Rep. 2016 Nov 22;17(9):2195-2209. doi: 10.1016/j.celrep.2016.10.085.

44.

HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98.

Sok D, Burton DR.

Immunity. 2016 Nov 15;45(5):958-960. doi: 10.1016/j.immuni.2016.10.033.

45.

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.

van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW.

Nat Microbiol. 2016 Nov 14;2:16199. doi: 10.1038/nmicrobiol.2016.199.

46.

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.

Larrick JW, Alfenito MR, Scott JK, Parren PW, Burton DR, Bradbury AR, Lemere CA, Messer A, Huston JS, Carter PJ, Veldman T, Chester KA, Schuurman J, Adams GP, Reichert JM.

MAbs. 2016 Nov/Dec;8(8):1425-1434. Epub 2016 Aug 24.

47.

Reproducing SIVΔnef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines.

Voss JE, Macauley MS, Rogers KA, Villinger F, Duan L, Shang L, Fink EA, Andrabi R, Colantonio AD, Robinson JE, Johnson RP, Burton DR, Haase AT.

AIDS. 2016 Oct 23;30(16):2427-2438.

48.

Correction: Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.

Jardine JG, Sok D, Julien JP, Briney B, Sarkar A, Liang CH, Scherer EM, Henry Dunand CJ, Adachi Y, Diwanji D, Hsueh J, Jones M, Kalyuzhniy O, Kubitz M, Spencer S, Pauthner M, Saye-Francisco KL, Sesterhenn F, Wilson PC, Galloway DA, Stanfield RL, Wilson IA, Burton DR, Schief WR.

PLoS Pathog. 2016 Sep 14;12(9):e1005905. doi: 10.1371/journal.ppat.1005905. eCollection 2016 Sep.

49.

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.

Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WR.

Immunity. 2016 Sep 20;45(3):483-496. doi: 10.1016/j.immuni.2016.08.016. Epub 2016 Sep 8.

50.

The effects of acoustic vibration on fibroblast cell migration.

Mohammed T, Murphy MF, Lilley F, Burton DR, Bezombes F.

Mater Sci Eng C Mater Biol Appl. 2016 Dec 1;69:1256-62. doi: 10.1016/j.msec.2016.07.037. Epub 2016 Jul 18.

PMID:
27612824

Supplemental Content

Loading ...
Support Center